| Symbol | NUVB |
|---|---|
| Name | NUVATION BIO INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 1500 BROADWAY,SUITE 1401, NEW YORK, New York, 10036, United States |
| Telephone | +1 332 208-6102 |
| Fax | — |
| — | |
| Website | https://www.nuvationbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001811063 |
| Description | Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The companys proprietary portfolio includes around six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Additional info from NASDAQ: |
2026-08-20 12:00
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma
Read more
2026-08-19 20:30
📋 GARY HATTERSLEY (Officer) plans to sell 100K shares of Nuvation Bio Inc. (at $6.96 each, total $696K) Filed: Aug 19, 2026 | ID: 008412
Read more
2026-08-06 11:30
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Read more
2026-07-22 20:05
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Read more
2026-07-17 22:27
Sauvage Philippe 🟡 adjusted position in 0 shares (2 derivative) of Nuvation Bio Inc. (NUVB) at $2.17 Transaction Date: Jul 15, 2026 | Filing ID: 000008
Read more
2026-07-06 21:09
Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering
Read more
2026-06-26 18:29
New Form FWP - Nuvation Bio Inc. <b>Filed:</b> 2026-06-26 <b>AccNo:</b> 0001193125-26-285741 <b>Size:</b> 47 KB
Read more
2026-06-26 03:58
Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06841874 | Expanded Access Program of Taletrectinib in Patients With Advanced or Metastati… | — | Lung Neoplasms | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT07703436 | Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Gliom… | Phase2 | Grade 2 IDH1-mutant Glioma | Not_Yet_Recruiting | 2027-03-01 | 2032-03-01 | ClinicalTrials.gov |
| NCT07712757 | Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Muta… | Phase3 | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation | Not_Yet_Recruiting | 2027-03-01 | 2032-03-01 | ClinicalTrials.gov |
| NCT07742384 | Study on the Effect of Famotidine on Pharmacokinetics of Taletrectinib | Phase1 | Healthy Adult Participants | Not_Yet_Recruiting | 2026-08-01 | 2027-02-02 | ClinicalTrials.gov |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positi… | Phase3 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2025-08-21 | 2033-08-30 | ClinicalTrials.gov |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tum… | Phase1 | Advanced Solid Tumor | Active_Not_Recruiting | 2024-03-14 | 2027-10-01 | ClinicalTrials.gov |
| NCT05303519 | SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase3 | Glioma | Recruiting | 2023-06-05 | 2030-12-01 | ClinicalTrials.gov |
| NCT05609929 | Study the Effect of Omeprazole on AB-106 Pharmacokinetics | Phase1 | Pharmacokinetic Study | Completed | 2022-11-02 | 2023-01-20 | ClinicalTrials.gov |
| NCT05577416 | A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma | Early_Phase1 | Glioma | Completed | 2022-10-11 | 2025-03-26 | ClinicalTrials.gov |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | Phase1 | Prostate Cancer | Withdrawn | 2022-09-01 | 2026-07-01 | ClinicalTrials.gov |
| NCT05191004 | Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC | Phase1 | Advanced Breast Cancer | Withdrawn | 2022-09-01 | 2026-09-01 | ClinicalTrials.gov |
| NCT05252390 | NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adul… | Phase1 | Advanced Solid Tumor | Terminated | 2022-03-29 | 2024-07-15 | ClinicalTrials.gov |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2021-09-01 | 2027-12-01 | ClinicalTrials.gov |
| NCT05357820 | A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itracon… | Phase1 | Solid Tumor | Completed | 2021-07-19 | 2021-12-03 | ClinicalTrials.gov |
| NCT05357911 | A Study on the Effect of AB-106 on the Pharmacokinetics of Digoxin | Phase1 | Solid Tumor | Completed | 2021-07-13 | 2021-12-03 | ClinicalTrials.gov |
| NCT04617054 | Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fus… | Phase2 | Solid Tumor | Terminated | 2021-06-01 | 2024-12-06 | ClinicalTrials.gov |
| NCT04541225 | Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and … | Phase1 | Glioma | Terminated | 2020-12-08 | 2022-08-31 | ClinicalTrials.gov |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | Phase2 | Non Small Cell Lung Cancer | Active_Not_Recruiting | 2020-07-07 | 2027-06-01 | ClinicalTrials.gov |
| NCT02279433 | A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetic… | Phase1 | Solid Tumors | Completed | 2014-09-01 | 2019-03-01 | ClinicalTrials.gov |
Total clinical trials: 19
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Safusidenib | Other | Phase PHASE2 | Grade 2 IDH1-mutant Glioma | NOT_YET_RECRUITING | NCT07703436 |
| Taletrectinib,Famotidine | Other | Phase PHASE1 | Healthy Adult Participants | NOT_YET_RECRUITING | NCT07742384 |
| Taletrectinib, Famotidine | Other | Phase PHASE1 | Healthy Adult Participants | NOT_YET_RECRUITING | NCT07742384 |
| Taletrectinib | Other | Phase PHASE1 | Healthy Adult Participants | NOT_YET_RECRUITING | NCT07742384 |
| Placebo | Other | Phase PHASE3 | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation | NOT_YET_RECRUITING | NCT07712757 |
| Safusidenib | Other | Phase PHASE3 | Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation | NOT_YET_RECRUITING | NCT07712757 |
| Placebo | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| safusidenib | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Placebo | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| safusidenib | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Enzalutamide | Other | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT05191017 |
| NUV-422 | Other | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT05191017 |
| Fulvestrant | Other | Phase PHASE1 | Advanced Breast Cancer | WITHDRAWN | NCT05191004 |
| NUV-422 | Other | Phase PHASE1 | Advanced Breast Cancer | WITHDRAWN | NCT05191004 |
| NUV-422 | Other | Phase PHASE1 | Glioma | TERMINATED | NCT04541225 |
| Multiple administration of omeprazole Single administration of AB-106 | Other | Phase PHASE1 | Pharmacokinetic Study | COMPLETED | NCT05609929 |
| AB-106, digoxin | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357911 |
| AB-106, Rifampicin | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| AB-106, Itraconazole | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| DS6051b | Other | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02279433 |
| NUV-1511 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06334432 |
| Part B: Safusidenib Erbumine | Other | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Surgery (maximal resection) | Procedure | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Part A: Safusidenib Erbumine | Other | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Biopsy | Other | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Enzalutamide | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Olaparib | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| NUV-868 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Taletrectinib | Other | Preclinical | Lung Neoplasms | NO_LONGER_AVAILABLE | NCT06841874 |
| Taletrectinib | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04919811 |
| AB-106 | Other | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04617054 |
| AB-106 | Other | Phase PHASE2 | Non Small Cell Lung Cancer | ACTIVE_NOT_RECRUITING | NCT04395677 |
| Placebo | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| safusidenib | Other | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Placebo | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Taletrectinib | Other | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| Crizotinib | DRUG | Phase PHASE3 | Non Small Cell Lung Cancer | RECRUITING | NCT06564324 |
| NUV-1511 | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06334432 |
| Multiple administration of omeprazole Single administration of AB-106 | DRUG | Phase PHASE1 | Pharmacokinetic Study | COMPLETED | NCT05609929 |
| Part B: Safusidenib Erbumine | DRUG | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Surgery (maximal resection) | PROCEDURE | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Part A: Safusidenib Erbumine | DRUG | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| Biopsy | PROCEDURE | Phase EARLY_PHASE1 | Glioma | COMPLETED | NCT05577416 |
| AB-106, digoxin | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357911 |
| AB-106, Rifampicin | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| AB-106, Itraconazole | DRUG | Phase PHASE1 | Solid Tumor | COMPLETED | NCT05357820 |
| Placebo | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| safusidenib | DRUG | Phase PHASE3 | Glioma | RECRUITING | NCT05303519 |
| Olaparib | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| NUV-868 | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Enzalutamide | DRUG | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT05252390 |
| Fulvestrant | DRUG | Phase PHASE1 | Advanced Breast Cancer | WITHDRAWN | NCT05191004 |
| Taletrectinib | DRUG | Phase PHASE3 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07154706 |
| NUV-422 | DRUG | Phase PHASE1 | Prostate Cancer | WITHDRAWN | NCT05191017 |
| AB-106 | DRUG | Phase PHASE2 | Solid Tumor | TERMINATED | NCT04617054 |
| Patient-reported outcomes (PROs) | OTHER | Preclinical | Cancer | RECRUITING | NCT04151342 |
| Cancer treatment with tyrosine kinase inhibitors (TKIs) or other molecularly targeted therapeutic agents. | DRUG | Preclinical | Cancer | RECRUITING | NCT04151342 |
| DS6051b | DRUG | Phase PHASE1 | Solid Tumors | COMPLETED | NCT02279433 |
Total products: 90